No information is available on the clinical use of trastuzumab emtansine during breastfeeding. Because trastuzumab is a large protein molecule with a molecular weight of 145,531 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. However, emtansine (DM1) is a small-molecule microtubule inhibitory drug, which might be excreted into milk. The manufacturer recommends that breastfeeding be discontinued during trastuzumab deruxtecan therapy and for 7 months after the last dose.
关于曲妥珠单抗（ado）曲妥珠单抗（ado）用于母乳喂养期间的临床应用尚无可用信息。由于曲妥珠单抗是一种分子量为145,531道尔顿的大分子蛋白质，乳汁中的含量可能非常低。它也可能在婴儿胃肠道中部分被破坏，婴儿的吸收可能微乎其微。然而，ado曲妥珠单抗（ado）ado（DM1）是一种小分子微管抑制药物，可能会排泄到乳汁中。制造商建议在曲妥珠单抗（ado）ado治疗期间及最后一剂后7个月内停止母乳喂养。
Zotero 插件